NCT02009852

Brief Summary

The Role of microRNA-29b in the Oral Squamous Cell Carcinoma

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 9, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 12, 2013

Completed
20 days until next milestone

Study Start

First participant enrolled

January 1, 2014

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Last Updated

December 12, 2013

Status Verified

December 1, 2013

Enrollment Period

11 months

First QC Date

December 9, 2013

Last Update Submit

December 9, 2013

Conditions

Keywords

microRNA-29bOral squamous cell carcinomamigrationprognosis

Outcome Measures

Primary Outcomes (1)

  • microRNA-29b

    3 years

Study Arms (1)

Oral cancer

Subjects who suffer from oral cancer. Subjects must: Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery. In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery. Before the surgery site staff must: Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Medical center

You may qualify if:

  • Cancer of the oral cavity.

You may not qualify if:

  • pregnant woman
  • refuse the surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital research Ethics Committee

Taipei, 10048, Taiwan

Location

Related Publications (20)

  • Ambros V. The functions of animal microRNAs. Nature. 2004 Sep 16;431(7006):350-5. doi: 10.1038/nature02871.

    PMID: 15372042BACKGROUND
  • Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10. doi: 10.1073/pnas.0707628104. Epub 2007 Sep 21.

    PMID: 17890317BACKGROUND
  • Pigazzi M, Manara E, Baron E, Basso G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res. 2009 Mar 15;69(6):2471-8. doi: 10.1158/0008-5472.CAN-08-3404. Epub 2009 Mar 3.

    PMID: 19258499BACKGROUND
  • Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010 Mar;12(3):247-56. doi: 10.1038/ncb2024. Epub 2010 Feb 21.

    PMID: 20173740BACKGROUND
  • Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007 Oct 11;449(7163):682-8. doi: 10.1038/nature06174. Epub 2007 Sep 26.

    PMID: 17898713BACKGROUND
  • Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, Martin SE, Stephens R, Caplen NJ. MicroRNAs and genomic instability. Semin Cancer Biol. 2007 Feb;17(1):65-73. doi: 10.1016/j.semcancer.2006.10.004. Epub 2006 Oct 26.

    PMID: 17113784BACKGROUND
  • Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993 Jan 21;328(3):184-94. doi: 10.1056/NEJM199301213280306. No abstract available.

    PMID: 8417385BACKGROUND
  • Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003 Jun;3(6):453-8. doi: 10.1038/nrc1098.

    PMID: 12778135BACKGROUND
  • Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006 Aug;12(8):895-904. doi: 10.1038/nm1469. No abstract available.

    PMID: 16892035BACKGROUND
  • Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006 Nov 17;127(4):679-95. doi: 10.1016/j.cell.2006.11.001.

    PMID: 17110329BACKGROUND
  • Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G. CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol. 2010 Jul;12(7):701-10. doi: 10.1093/neuonc/nop076. Epub 2010 Feb 8.

    PMID: 20511186BACKGROUND
  • Kok SH, Hong CY, Lin SK, Lee JJ, Chiang CP, Kuo MY. Establishment and characterization of a tumorigenic cell line from areca quid and tobacco smoke-associated buccal carcinoma. Oral Oncol. 2007 Aug;43(7):639-47. doi: 10.1016/j.oraloncology.2006.07.007. Epub 2006 Oct 25.

    PMID: 17070096BACKGROUND
  • Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002 Jul-Aug;52(4):195-215. doi: 10.3322/canjclin.52.4.195.

    PMID: 12139232BACKGROUND
  • Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC, Kuo ML. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst. 2006 Jul 19;98(14):984-95. doi: 10.1093/jnci/djj242.

    PMID: 16849681BACKGROUND
  • Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002.

    PMID: 19167326BACKGROUND
  • Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez Y Baena R, Gaetani P, Pelicci G, Allavena P. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer. 2010 Dec;46(18):3383-92. doi: 10.1016/j.ejca.2010.07.022. Epub 2010 Aug 19.

    PMID: 20728344BACKGROUND
  • Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadiere C, Prevot S, Machelon V, Balabanian K. Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS One. 2011;6(7):e21546. doi: 10.1371/journal.pone.0021546. Epub 2011 Jul 7.

    PMID: 21750716BACKGROUND
  • Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, Ogawa M, Nakamura Y, Arakawa H. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res. 2000 Jul 15;60(14):3722-6.

    PMID: 10919640BACKGROUND
  • Moutasim KA, Jenei V, Sapienza K, Marsh D, Weinreb PH, Violette SM, Lewis MP, Marshall JF, Fortune F, Tilakaratne WM, Hart IR, Thomas GJ. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J Pathol. 2011 Feb;223(3):366-77. doi: 10.1002/path.2786. Epub 2010 Oct 25.

    PMID: 21171082BACKGROUND
  • Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009 Nov 25;139(5):871-90. doi: 10.1016/j.cell.2009.11.007.

    PMID: 19945376BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

tissue, serum, saliva

MeSH Terms

Conditions

Mouth NeoplasmsSquamous Cell Carcinoma of Head and Neck

Condition Hierarchy (Ancestors)

Head and Neck NeoplasmsNeoplasms by SiteNeoplasmsMouth DiseasesStomatognathic DiseasesCarcinoma, Squamous CellCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • Shin-Jung Cheng, DDS, MS, PhD

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shin-Jung Cheng, DDS, MS, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 9, 2013

First Posted

December 12, 2013

Study Start

January 1, 2014

Primary Completion

December 1, 2014

Last Updated

December 12, 2013

Record last verified: 2013-12

Locations